News

Research is increasingly demonstrating that genetic mutations play a significant role in the development of ALS: for example, the C9orf72 gene is one of the most prominent genetic causes of the disease. With the scientific community abuzz about CRISPR/CAS9,…

Updated May 13, 2022 Highlights: In May 2017 the United States Food and Drug Administration approved edaravone (also referred to as Radicava and Radicut) for the treatment of ALS. It’s the second ALS drug to be approved in the US.…

ALS Canada and Brain Canada award $4.5 million in research funding The ALS Society of Canada (ALS Canada), in partnership with Brain Canada, today announced $4.5 million in funding for nine new ALS research projects. This means that since the…

The generosity of Canadians has helped three early-career researchers to make ALS the focus of their work in the country’s labs and academic institutions. The research funding, which totals more than $1 million, has been awarded through the ALS Canada…

Earlier this week researchers announced that the gene NEK1 has been found to play a significant role in the development of amyotrophic lateral sclerosis (ALS). This landmark discovery is the result of an 11-country research collaboration that was funded through…

We are pleased to advise you that the Government of Canada has announced the activation of the extension of the Compassionate Care Benefit (CCB) from six to 26 weeks. Effective January 3, 2016, caregivers can now claim up to $13,624…

A large consortium of researchers from six countries have definitively identified a new ALS gene called TANK-binding kinase 1 (TBK1) by performing a rigorous study that involved sequencing of more than 2800 people with ALS compared with more than 6000…